Advances In The Molecular Pathogenesis And Targeted Therapy Of Psoriasis
May 2025
in “
Galen Medical Journal
”
Psoriasis affects 2-3% of the global population and involves immune dysregulation, keratinocyte dysfunction, and genetic/epigenetic changes, with comorbidities like psoriatic arthritis and cardiovascular disease. Recent advances using single-cell RNA sequencing and transcriptomics have identified key mechanisms such as GSDME-mediated pyroptosis and IL-23/IL-17 axis activation. Targeted therapies, including IL-17 inhibitors like secukinumab and IL-23 inhibitors like risankizumab, show promise, while novel treatments like hyperforin and Deu@Cal microneedles are in early stages. Challenges include adverse events, treatment resistance, and personalization gaps. Future efforts focus on multi-omics integration and combination therapies to enhance precision medicine in psoriasis management.